Bristol Myers' Two Opdivo Based Regimes Under FDA Review For Esophageal Cancer

  • The FDA has accepted for review Bristol Myers Squibb & Co Inc's BMY supplemental marketing applications seeking approval for two Opdivo (nivolumab) based combo regimes for esophageal squamous cell carcinoma.
  • The application cover Opdivo / Yervoy (ipilimumab) and Opdivo / fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for adult patients with unresectable advanced, recurrent or metastatic ESCC.
  • The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 28, 2022.
  • In CheckMate -648, both Opdivo-based treatment combinations demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to chemotherapy.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: BMY stock is up 0.75% at $60.68 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsEsophageal Cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!